Suppr超能文献

自然随机分配降低低密度脂蛋白胆固醇对由NPC1L1、HMGCR或两者的多态性介导的冠心病风险的影响:一项2×2析因孟德尔随机化研究。

Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study.

作者信息

Ference Brian A, Majeed Faisal, Penumetcha Raju, Flack John M, Brook Robert D

机构信息

Division of Translational Research and Clinical Epidemiology, Wayne State University School of Medicine, Detroit, Michigan; Division of Cardiovascular Medicine, Wayne State University School of Medicine, Detroit, Michigan; Department of Internal Medicine, Wayne State University School of Medicine, Detroit, Michigan.

Division of Translational Research and Clinical Epidemiology, Wayne State University School of Medicine, Detroit, Michigan.

出版信息

J Am Coll Cardiol. 2015 Apr 21;65(15):1552-61. doi: 10.1016/j.jacc.2015.02.020. Epub 2015 Mar 11.

Abstract

BACKGROUND

Considerable uncertainty exists as to whether lowering low-density lipoprotein cholesterol (LDL-C) by inhibiting the Niemann-Pick C1-Like 1 (NPC1L1) receptor with ezetimibe, either alone or in combination with a 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) inhibitor (statin), will reduce the risk of coronary heart disease (CHD).

OBJECTIVES

This study evaluated the effect of naturally random allocation to lower LDL-C mediated by polymorphisms in the NPC1L1 gene (target of ezetimibe), the HMGCR gene (target of statins), or both (target of combination therapy) on the risk of CHD.

METHODS

We constructed NPC1L1 and HMGCR genetic LDL-C scores to naturally randomize participants into 4 groups: reference, lower LDL-C mediated by NPC1L1 polymorphisms, lower LDL-C mediated by HMGCR polymorphisms, or lower LDL-C mediated by polymorphisms in both NPC1L1 and HMGCR. We compared the risk of CHD (fatal or nonfatal myocardial infarction) among each group using a 2 × 2 factorial mendelian randomization study design.

RESULTS

A total of 108,376 persons (10,464 CHD events) from 14 studies were included. There were no significant differences in baseline characteristics among the 4 groups, thus confirming that allocation was random. Compared to the reference group, the NPC1L1 group had 2.4 mg/dl lower LDL-C and 4.8% lower risk of CHD (odds ratio [OR]: 0.952, 95% confidence interval [CI]: 0.920 to 0.985); whereas the HMGCR group had 2.9 mg/dl lower LDL-C and a similar 5.3% lower risk of CHD (OR: 0.947, 95% CI: 0.909 to 0.986). The group with lower LDL-C mediated by both NPC1L1 and HMGCR polymorphisms had 5.8 mg/dl additively lower LDL-C and a 10.8% log-linearly additive lower risk of CHD (OR: 0.892, 95% CI: 0.854 to 0.932).

CONCLUSIONS

The effect of lower LDL-C on the risk of CHD mediated by polymorphisms in NPC1L1, HMGCR, or both is approximately the same per unit lower LDL-C and log-linearly proportional to the absolute exposure to lower LDL-C.

摘要

背景

关于通过依折麦布抑制尼曼-匹克C1样1(NPC1L1)受体单独或与3-羟基-3-甲基戊二酰辅酶A还原酶(HMGCR)抑制剂(他汀类药物)联合降低低密度脂蛋白胆固醇(LDL-C)是否会降低冠心病(CHD)风险,存在相当大的不确定性。

目的

本研究评估了由NPC1L1基因(依折麦布的作用靶点)、HMGCR基因(他汀类药物的作用靶点)或两者(联合治疗的作用靶点)的多态性介导的自然随机分配降低LDL-C对CHD风险的影响。

方法

我们构建了NPC1L1和HMGCR基因LDL-C评分,将参与者自然随机分为4组:参照组、由NPC1L1多态性介导的LDL-C降低组、由HMGCR多态性介导的LDL-C降低组或由NPC1L1和HMGCR多态性介导的LDL-C降低组。我们使用2×2析因孟德尔随机化研究设计比较了每组中CHD(致命或非致命心肌梗死)的风险。

结果

纳入了来自14项研究的总共108,376人(10,464例CHD事件)。4组之间的基线特征无显著差异,从而证实了分配是随机的。与参照组相比,NPC1L1组的LDL-C降低了2.4mg/dl,CHD风险降低了4.8%(比值比[OR]:0.952,95%置信区间[CI]:0.920至0.985);而HMGCR组的LDL-C降低了2.9mg/dl,CHD风险同样降低了5.3%(OR:

相似文献

3
Genetic association of lipid-lowering drugs with aortic aneurysms: a Mendelian randomization study.
Eur J Prev Cardiol. 2024 Jul 23;31(9):1132-1140. doi: 10.1093/eurjpc/zwae044.

引用本文的文献

1
Human Genetics Informing Drug Development in Cardiovascular Disease: Interleukin-6 Signaling as a Case Study.
Circ Genom Precis Med. 2025 Aug;18(4):e005103. doi: 10.1161/CIRCGEN.125.005103. Epub 2025 Jul 28.
3
NPC1L1 Drives Osteoporosis by Activating the C/EBPα/Cyp27a1/27-Hydroxycholesterol Axis: A Novel Therapeutic Target for Bone Loss.
FASEB Bioadv. 2025 May 8;7(6):e70020. doi: 10.1096/fba.2025-00044. eCollection 2025 Jun.
4
Novel Concepts for the Estimation of Lifetime Cardiovascular Risk.
High Blood Press Cardiovasc Prev. 2025 Jun 9. doi: 10.1007/s40292-025-00724-x.
6
UDP-Glucose Ceramide Glucosyltransferase Inhibition, Immune Cell Mediation, and Endometriosis Risk: A Mendelian Randomization Study.
Int J Womens Health. 2025 May 24;17:1497-1509. doi: 10.2147/IJWH.S509603. eCollection 2025.
7
Causal relationship between schizophrenia and five types of dementia: A bidirectional two-sample Mendelian randomization study.
PLoS One. 2025 May 8;20(5):e0322752. doi: 10.1371/journal.pone.0322752. eCollection 2025.

本文引用的文献

1
Inactivating mutations in NPC1L1 and protection from coronary heart disease.
N Engl J Med. 2014 Nov 27;371(22):2072-82. doi: 10.1056/NEJMoa1405386. Epub 2014 Nov 12.
3
Effects of extended-release niacin with laropiprant in high-risk patients.
N Engl J Med. 2014 Jul 17;371(3):203-12. doi: 10.1056/NEJMoa1300955.
4
Lipid lowering with PCSK9 inhibitors.
Nat Rev Cardiol. 2014 Oct;11(10):563-75. doi: 10.1038/nrcardio.2014.84. Epub 2014 Jun 24.
5
Discovery and refinement of loci associated with lipid levels.
Nat Genet. 2013 Nov;45(11):1274-1283. doi: 10.1038/ng.2797. Epub 2013 Oct 6.
6
Large-scale association analysis identifies new risk loci for coronary artery disease.
Nat Genet. 2013 Jan;45(1):25-33. doi: 10.1038/ng.2480. Epub 2012 Dec 2.
7
An integrated map of genetic variation from 1,092 human genomes.
Nature. 2012 Nov 1;491(7422):56-65. doi: 10.1038/nature11632.
9
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study.
Lancet. 2012 Aug 11;380(9841):572-80. doi: 10.1016/S0140-6736(12)60312-2. Epub 2012 May 17.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验